Polycystic kidney disease (PKD) is a hereditary disorder of renal cyst formation causing gradual enlargement of both kidneys, sometimes with progression to renal failure. Almost all forms are caused by a familial genetic mutation. Symptoms and signs include flank and abdominal pain, hematuria, and hypertension. Diagnosis is by CT or ultrasonography. Treatment is symptomatic before renal failure and with dialysis or transplantation afterward.
Inheritance of PKD is autosomal dominant or recessive; sporadic cases occur rarely. Autosomal dominant polycystic kidney disease (ADPKD) has an incidence of 1/1000 and accounts for about 5% of patients with end-stage renal disease requiring replacement therapy. Clinical manifestations are rare before adulthood, but penetrance is essentially complete; all patients ≥ 80 yr have some signs. In contrast, autosomal recessive PKD is rare; incidence is 1/10,000. It frequently causes renal failure during childhood (see Autosomal recessive polycystic kidney disease).
In 86 to 96% of cases, ADPKD is caused by mutations in the PKD1 gene on chromosome 16, which codes for the protein polycystin 1; most other cases are caused by mutations in the PKD2 gene on chromosome 4, which codes for polycystin 2. A few familial cases are unrelated to either locus.
Polycystin 1 may regulate tubular epithelial cell adhesion and differentiation; polycystin 2 may function as an ion channel, with mutations causing fluid secretion into cysts. Mutations in these proteins may alter the function of renal cilia, which enable tubular cells to sense flow rates. A leading hypothesis proposes that tubular cell proliferation and differentiation are linked to flow rate and that ciliary dysfunction may thus lead to cystic transformation.
Early in the disorder, tubules dilate and slowly fill with glomerular filtrate. Eventually, the tubules separate from the functioning nephron and fill with secreted rather than filtered fluid, forming cysts. Hemorrhage into cysts may occur, causing hematuria. Patients are also at higher risk of acute pyelonephritis, cyst infections, and urinary calculi (in 20%). Vascular sclerosis and interstitial fibrosis eventually develop via unknown mechanisms and typically affect < 10% of tubules; nonetheless, renal failure develops in about 35 to 45% of patients by age 60.
Extrarenal manifestations are common:
Symptoms and Signs
ADPKD usually causes no symptoms initially; one half of patients remain asymptomatic, never develop renal insufficiency or failure, and are never diagnosed. Most patients who develop symptoms do so by the end of their 20s. Symptoms include low-grade flank, abdominal, and lower back pain due to cystic enlargement and symptoms of infection. Acute pain, when it occurs, is usually due to hemorrhage into cysts or passage of a calculus. Fever is common with acute pyelonephritis, and rupture of cysts into the retroperitoneal space may cause a fever that can last for weeks. Hepatic cysts may cause right upper quadrant pain if they enlarge or become infected. Valvular disorders rarely cause symptoms but occasionally cause heart failure and require valvular replacement. Symptoms and signs of unruptured cerebral aneurysm can be absent or may include headache, nausea and vomiting, and cranial nerve deficits; these manifestations warrant immediate intervention (see Sidebar 1: Vascular Lesions in the Brain).
Signs are nonspecific and include hematuria and hypertension (each in about 40 to 50%) and, in 20% of patients, proteinuria in the subnephrotic range (< 3.5g/24 h in adults). Anemia is less common than in other types of chronic kidney disease, presumably because erythropoietin production is preserved. In advanced disease, the kidneys may become grossly enlarged and palpable, causing fullness in the upper abdomen and flank.
The diagnosis is suspected in patients with the following:
Patients should be counseled before undergoing diagnostic testing, particularly if they are asymptomatic. For example, many authorities recommend against testing asymptomatic young patients because no disease-modifying treatment is effective at this age and diagnosis has potential negative effects on ability to obtain life insurance on favorable terms and on mood.
Diagnosis is usually by imaging, showing extensive and bilateral cystic changes throughout the kidneys, which are typically enlarged and have a moth-eaten appearance due to cysts that displace functional tissue. These changes develop with age and are less often present or obvious in younger patients. Ultrasonography is usually done first. If ultrasonography results are inconclusive, CT or MRI, which are both more sensitive (particularly when done using contrast), is done. MRI is especially useful for measuring cyst and kidney volume. These measurements predict risk of progression to chronic kidney disease and end-stage renal disease, often before changes in routine laboratory studies. For example, cyst size and kidney size predict 8 yr risk of chronic kidney disease more accurately than age, degree of proteinuria, or serum BUN, or creatinine. Urinalysis, renal function tests, and CBC are done, but results are not specific.
Urinalysis detects mild proteinuria and microscopic or macroscopic hematuria. Gross hematuria may be due to a dislodged calculus or to hemorrhage from a ruptured cyst. Pyuria is common even without bacterial infection; thus diagnosis of infection should be based on culture results and clinical findings (eg, dysuria, fever, flank pain) as well as urinalysis. Initially, BUN and creatinine are normal or only mildly elevated, but they slowly increase, especially when hypertension is present. Rarely, CBC detects polycythemia.
Patients with symptoms of cerebral aneurysm require high-resolution CT or magnetic resonance angiography. However, most experts do not recommend routine screening for cerebral aneurysm in asymptomatic patients. A reasonable approach is to screen patients with ADPKD who have a family history of hemorrhagic stroke or cerebral aneurysm.
Genetic testing for PKD mutations is currently reserved for any of the following:
Genetic counseling is recommended for 1st-degree relatives of patients with ADPKD.
By age 75, 50 to 75% of patients with ADPKD require renal replacement therapy (dialysis or transplantation). Predictors of more rapid progression to renal failure include the following:
ADPKD does not increase risk of renal cancer, but if patients with ADPKD develop renal cancer, it is more likely to be bilateral. Renal cancer rarely causes death. Patients usually die of heart disease (sometimes valvular), disseminated infection, or ruptured cerebral aneurysm.
Strict BP control is essential. Typically an ACE inhibitor or angiotensin receptor blocker is used. In addition to controlling BP, these drugs help block angiotensin and aldosterone, growth factors that contribute to renal scarring and loss of renal function. UTIs should be treated promptly. Percutaneous aspiration of cysts may help relieve severe pain due to hemorrhage or compression but has no effect on long-term outcome. Nephrectomy is an option to relieve severe symptoms due to massive kidney enlargement (eg, pain, hematuria) or recurrent UTIs. Hemodialysis, peritoneal dialysis, or kidney transplantation is required in patients who develop chronic renal failure. ADPKD does not recur in grafts. With dialysis, patients with ADPKD maintain higher Hb levels than any other group of patients with renal failure. Mammalian target of rapamycin (mTOR) inhibitors may slow the increase in kidney volume but not the decline in renal function; thus, they are not typically used in routine practice. Tolvaptan, a vasopressin receptor 2 antagonist, is a new drug that may benefit patients with ADPKD. Tolvaptan appears to slow increase in renal volume and decline in renal function, but it can cause adverse effects via free water diuresis (eg, thirst, polydipsia, polyuria) that can make adherence difficult. Also, tolvaptan has been reported to cause severe liver failure, and data on long-term outcomes are not yet sufficient to confirm a favorable benefit/ harm balance, so use of tolvaptan is not yet recommended for ADPKD.
Last full review/revision September 2013 by Navin Jaipaul, MD, MHS
Content last modified November 2013